Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the nineteen research firms that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $232.32.
ALNY has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, December 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, January 18th. Wells Fargo & Company initiated coverage on Alnylam Pharmaceuticals in a report on Friday, December 8th. They issued an “equal weight” rating and a $171.00 price objective for the company. BMO Capital Markets decreased their price objective on Alnylam Pharmaceuticals from $250.00 to $234.00 and set an “outperform” rating for the company in a research report on Tuesday, October 10th. Finally, Oppenheimer cut shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 11th.
Insider Transactions at Alnylam Pharmaceuticals
Hedge Funds Weigh In On Alnylam Pharmaceuticals
Several institutional investors have recently modified their holdings of the company. Capital Advisors Ltd. LLC lifted its holdings in Alnylam Pharmaceuticals by 1,480.0% in the second quarter. Capital Advisors Ltd. LLC now owns 158 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 148 shares during the period. Quent Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. KB Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $35,000. Financial Gravity Asset Management Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter valued at about $132,000. Finally, Anchor Investment Management LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $38,000. Institutional investors own 93.98% of the company’s stock.
Alnylam Pharmaceuticals Price Performance
Shares of ALNY opened at $183.93 on Friday. The firm has a 50-day simple moving average of $181.60 and a two-hundred day simple moving average of $181.80. The stock has a market cap of $23.08 billion, a PE ratio of -44.43 and a beta of 0.47. Alnylam Pharmaceuticals has a 1-year low of $148.10 and a 1-year high of $234.70.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $2.76. The firm had revenue of $750.53 million for the quarter, compared to analyst estimates of $406.14 million. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- AI growth propels semiconductor stocks to new highs
- How to Invest in Fertilizer
- Discover leads financial stocks higher, but is trouble lurking?
- Upcoming IPO Stock Lockup Period, Explained
- How to buy stock: A step-by-step guide for beginners
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.